The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19

References

• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292. e6.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–456.
   PubMed Web of Science ®Google Scholar
• Krieger E, Vriend G. YASARA View - molecular graphics for all devices - from smartphones to workstations. Bioinformatics. 2014;30(20):2981–2982.
   PubMed Web of Science ®Google Scholar
• Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020;39(3):198–216.
   PubMed Web of Science ®Google Scholar
• Panda PK, Arul MN, Patel P, et al. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2. Sci Adv. 2020;6(28):eabb8097.
   PubMed Web of Science ®Google Scholar
• Calligari P, Bobone S, Ricci G, et al. Molecular investigation of SARS–CoV-2 proteins and their interactions with antiviral drugs. Viruses. 2020;12(4):445.
   PubMed Web of Science ®Google Scholar
• Liu DX, Fung TS, Chong KK, et al. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014;109:97–109.
   PubMed Web of Science ®Google Scholar
• Chernyshev A. Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved drugs. ChemRxiv. 2020;
   Google Scholar
• Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69
   PubMed Web of Science ®Google Scholar
• Zeng W, Liu G, Ma H, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527(3):618–623.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang G, Ouyang L. Promising inhibitors targeting M pro: an ideal strategy for anti-SARS-CoV-2 drug discovery. Sig Transduct Target Ther. 2020;5(1):1–2.
   PubMed Web of Science ®Google Scholar
• Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587(7835):657-662
   Web of Science ®Google Scholar
• Hillen HS, Kokic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584(7819):154–156.
   PubMed Web of Science ®Google Scholar
• Habtemariam S, Nabavi SF, Banach M, et al. Should we try SARS-CoV-2 helicase inhibitors for COVID-19 therapy? Arch Med Res. 2020; 51(7):733–735.
   Web of Science ®Google Scholar
• Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020;52(1):56–65.
   PubMed Web of Science ®Google Scholar
• Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347.
   PubMed Web of Science ®Google Scholar
• Trezza A, Iovinelli D, Santucci A, et al. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. Sci Rep. 2020;10(1):13866
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502.
   PubMed Web of Science ®Google Scholar
• Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.
   PubMed Web of Science ®Google Scholar
• Tu YF, Chien CS, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. IJMS. 2020;21(7):2657. doi: 10.3390/ijms21072657.
   Google Scholar
• Zhu N, Zhang D, Wang W, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019 [published January 24, 2020]. N Engl J Med. 2020; 382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Cheng VC, Lau SK, Woo PC, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660–694.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). 2020. Available on: https://www.who.int/emergencies/mers-cov/en/.
   Google Scholar
• Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836–848.
   PubMed Web of Science ®Google Scholar
• Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res. 2009;32(7):533–536.
   PubMed Web of Science ®Google Scholar
• Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801–1803.
   PubMed Web of Science ®Google Scholar
• Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236.
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic cleavage site in the spike protein of SARS-CoV-2 Is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–784 e5.
   PubMed Web of Science ®Google Scholar
• Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3(9):e202000786. doi: 10.26508/lsa.202000786.
   PubMed Web of Science ®Google Scholar
• Progress report on the coronavirus pandemic. Nature. 2020;584(7821):325.
   PubMed Web of Science ®Google Scholar
• Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687.
   PubMed Web of Science ®Google Scholar
• Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192.
   PubMed Web of Science ®Google Scholar
• Puelles VG, Lutgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590–592.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA. 2020;117(13):7001–7003.
   PubMed Web of Science ®Google Scholar
• Luan J, Jin X, Lu Y, et al. SARS-CoV-2 spike protein favors ACE2 from Bovidae and Cricetidae. J Med Virol. 2020;92(9):1649–1656. doi: 10.1002/jmv.25817.
   PubMed Web of Science ®Google Scholar
• Hu B, Ge X, Wang LF, et al. Bat origin of human coronaviruses. Virol J. 2015;12:221.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Cagliani R, Forni D, Clerici M, et al. Computational inference of selection underlying the evolution of the novel coronavirus, severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94(12):e00411. doi: 10.1128/JVI.00411-20.
   PubMed Web of Science ®Google Scholar
• Matyášek R, Kovařík A. Mutation patterns of human SARS-CoV-2 and Bat RaTG13 coronavirus genomes are strongly biased towards C > U transitions, indicating rapid evolution in their hosts. Genes. 2020;11(7):761.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr Biol. 2020;30(7):1346–1351.e2.
   PubMed Web of Science ®Google Scholar
• Ye ZW, Yuan S, Yuen KS, Fung SY, et al. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020;16(10):1686–1697.
   PubMed Web of Science ®Google Scholar
• Qin J, You C, Lin Q, et al. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. Sci Adv. 2020;6(33):eabc1202.
   PubMed Web of Science ®Google Scholar
• Dhakal BP, Sweitzer NK, Indik JH, et al. SARS-CoV-2 infection and cardiovascular disease: COVID-19 heart. Heart Lung Circ. 2020;29(7):973–987.
   PubMed Web of Science ®Google Scholar
• Yi Y, Lagniton PNP, Ye S, et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–1766.
   PubMed Web of Science ®Google Scholar
• Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020;128:104386.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831–840.
   PubMed Web of Science ®Google Scholar
• Jothimani D, Venugopal R, Abedin MF, et al. COVID-19 and the liver. J Hepatol. 2020;73(5):1231–1240.
   PubMed Web of Science ®Google Scholar
• Hong N, Yu W, Xia J, et al. Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19. Acta Ophthalmol. 2020;98(5):e649–e55. doi: 10.1111/aos.14445.
   PubMed Web of Science ®Google Scholar
• Amesty MA, Alió del Barrio JL, Alió JL. COVID-19 disease and ophthalmology: an update. Ophthalmol Ther. 2020;9(3):1–12.
   PubMedGoogle Scholar
• Baj J, Karakuła-Juchnowicz H, Teresiński G, et al. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020;9(6):1753.
   Web of Science ®Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230–232.
   PubMed Web of Science ®Google Scholar
• Violi F, Pastori D, Pignatelli P, et al. SARS-CoV-2 and myocardial injury: a role for Nox2? Intern Emerg Med. 2020;15(5):755–758.
   PubMed Web of Science ®Google Scholar
• Sorodoc V, Sorodoc L, Ungureanu D, et al. Cardiac troponin T and NT-proBNP as biomarkers of early myocardial damage in amitriptyline-induced cardiovascular toxicity in rats. Int J Toxicol. 2013;32(5):351–357. doi: 10.1177/1091581813503888.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020;9(3):215–221.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. doi: 10.1001/jamacardio.2020.0950.
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiology. 2020;5(11):1265–1273;
   PubMed Web of Science ®Google Scholar
• Nagel E, Puntmann VO. Errors in statistical numbers and data in study of cardiovascular magnetic resonance imaging in patients recently recovered From COVID-19. JAMA Cardiology. 2020:5(11):1307-1308.
   Web of Science ®Google Scholar
• Gabarre P, Dumas G, Dupont T, et al. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46(7):1339–1348.
   PubMed Web of Science ®Google Scholar
• Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690.
   PubMed Web of Science ®Google Scholar
• Huang J, Zheng M, Tang X, et al. Potential of SARS-CoV-2 to cause CNS infection: biologic fundamental and clinical experience. Front Neurol. 2020;11:659
   PubMed Web of Science ®Google Scholar
• Mercante G, Ferreli F, De Virgilio A, et al. Prevalence of taste and smell dysfunction in coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020;146(8):723–728.
   PubMed Web of Science ®Google Scholar
• Desforges M, Le Coupanec A, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):14. doi: 10.3390/v12010014.
   PubMed Web of Science ®Google Scholar
• Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. 2020;71(15):889–890.
   PubMed Web of Science ®Google Scholar
• Rubino F, Cohen RV, Mingrone G, et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol. 2020;8(7):640–648. doi: 10.1016/S2213-8587(20)30157-1.
   PubMed Web of Science ®Google Scholar
• Liu F, Long X, Zhang B, et al. ACE2 expression in pancreas may cause pancreatic damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020;18(9):2128–2130. e2.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. Gastroenterology. 2020;159(1):367–370.
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040.
   PubMed Web of Science ®Google Scholar
• Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med. 2020;15(8):1375–1387. doi: 10.1007/s11739-020-02432-x.
   PubMed Web of Science ®Google Scholar
• Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149
   Web of Science ®Google Scholar
• Tatu AL, Nadasdy T, Nwabudike LC. Observations about sexual and other routes of SARS-CoV-2 (COVID-19) transmission and its prevention. Clin Exp Dermatol. 2020;45(6):761–762.
   PubMedGoogle Scholar
• Fraietta R, Pasqualotto FF, Roque M, et al. SARS-COV-2 and male reproductive health. JBRA Assist Reprod. 2020;24(3):347–350.
   PubMed Web of Science ®Google Scholar
• Li R, Yin T, Fang F, et al. Potential risks of SARS-CoV-2 infection on reproductive health. Reprod Biomed Online. 2020;41(1):89–95.
   PubMed Web of Science ®Google Scholar
• Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179(7):1029–1046.
   PubMed Web of Science ®Google Scholar
• Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20(8):453–454.
   PubMed Web of Science ®Google Scholar
• Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–346.
   PubMed Web of Science ®Google Scholar
• Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968–981.e7. doi: 10.1016/j.cell.2020.09.016.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Infection Prevention and Control of Epidemic-and Pandemic-prone Acute Respiratory Infections in Health Care. 2014. Available on: https://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_eng.pdf;jsessionid=41AA684FB64571CE8D8A453C4F2B2096?sequence=1.
   Google Scholar
• Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations. 2020. Available on: https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions.
   Google Scholar
• Tran K, Cimon K, Severn M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One. 2012;7(4):e35797
   PubMed Web of Science ®Google Scholar
• Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature. 2020;582(7813):557–560.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–1844.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–1567.
   PubMed Web of Science ®Google Scholar
• Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim HM, Lee EJ, et al. Detection and isolation of SARS-CoV-2 in serum, urine, and stool specimens of COVID-19 patients from the Republic of Korea. Osong Public Health Res Perspect. 2020;11(3):112–117.
   PubMedGoogle Scholar
• Peng L, Liu J, Xu W, et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. J Med Virol. 2020;92(9):1676–1680. doi: 10.1002/jmv.25936.
   PubMed Web of Science ®Google Scholar
• Chen L, Lou J, Bai Y, et al. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. Am J Gastroenterol. 2020;115(5):790
   PubMed Web of Science ®Google Scholar
• Ding S, Liang TJ. Is SARS-CoV-2 Also an enteric pathogen with potential fecal-oral transmission? A COVID-19 virological and clinical review. Gastroenterology. 2020;159(1):53–61.
   PubMed Web of Science ®Google Scholar
• Centeno-Tablante E, Medina-Rivera M, Finkelstein JL, et al. Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review. Ann N Y Acad Sci. 2020. doi: 10.1111/nyas.14477.
   Web of Science ®Google Scholar
• World Health Organization. Breastfeeding and COVID-19. 2020. Available on: https://www.who.int/news-room/commentaries/detail/breastfeeding-and-covid-19.
   Google Scholar
• Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020;144(7):799–805. doi: 10.5858/arpa.2020-0901-SA.
   PubMed Web of Science ®Google Scholar
• Auriti C, De Rose DU, Tzialla C, et al. Vertical transmission of SARS-CoV-2 (COVID-19): are hypotheses more than evidences? Am J Perinatol. 2020;37(S 02):S31–S8.
   PubMedGoogle Scholar
• U.S. Centers for Disease Control and Prevention. Contact Tracing for COVID-19. 2020. Available on: https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/contact-tracing.html.
   Google Scholar
• He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–675.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang D, Yang P, et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411–412.
   PubMed Web of Science ®Google Scholar
• Yu P, Zhu J, Zhang Z, et al. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis. 2020;221(11):1757–1761.
   PubMed Web of Science ®Google Scholar
• Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–2090.
   PubMed Web of Science ®Google Scholar
• Tong Z-D, Tang A, Li K-F, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26(5):1052–1054.
   PubMed Web of Science ®Google Scholar
• Salimi S, Hamlyn JM. COVID-19 and crosstalk with the hallmarks of aging. J Gerontol A Biol Sci Med Sci. 2020;75(9):e34–e41.
   PubMed Web of Science ®Google Scholar
• Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020;12(10):9959–9981.
   PubMedGoogle Scholar
• Severe Covid GG, Ellinghaus D, Degenhardt F, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522–1534.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Haralambieva IH, Crooke SN, et al. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020;296(1):205–219.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Deelen J, Gallina AM, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18(1):352.
   PubMed Web of Science ®Google Scholar
• Sawalha AH, Zhao M, Coit P, et al. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. 2020;215:108410. doi:.
   PubMed Web of Science ®Google Scholar
• Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 2020;11:1800.
   PubMed Web of Science ®Google Scholar
• Callaway E. The coronavirus is mutating - does it matter? Nature. 2020;585(7824):174–177.
   PubMed Web of Science ®Google Scholar
• Becchetti L, Conzo G, Conzo P, et al. Understanding the heterogeneity of adverse COVID-19 outcomes: the role of poor quality of air and lockdown decisions. Available at SSRN 3572548. 2020. doi: .
   Google Scholar
• Kaye M. SARS-associated coronavirus replication in cell lines. Emerg Infect Dis. 2006;12(1):128–133.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Bales KL, Capitanio JP, et al. Why primate models matter. Am J Primatol. 2014;76(9):801–827.
   PubMed Web of Science ®Google Scholar
• Johansen MD, Irving A, Montagutelli X, et al. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol. 2020;13(6):877–891.
   PubMed Web of Science ®Google Scholar
• Nagata N, Iwata N, Hasegawa H, et al. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. J Virol. 2007;81(4):1848–1857.
   PubMed Web of Science ®Google Scholar
• Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007;3(1):e5.
   PubMed Web of Science ®Google Scholar
• Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397–412.
   PubMed Web of Science ®Google Scholar
• Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–98.
   PubMed Web of Science ®Google Scholar
• Kim YI, Kim SG, Kim SM, et al. Infection and rapid transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe. 2020;27(5):704–709 e2.
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci USA. 2020;117(28):16587–16595.
   PubMed Web of Science ®Google Scholar
• Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res. 2006;16(2):141–147.
   PubMed Web of Science ®Google Scholar
• Crowe JE. Host defense mechanisms against viruses. In book: Fetal and Neonatal Physiology. 5th ed. Elsevier. 2017;1175–1197.e7.
   Google Scholar
• Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81(2):548–557.
   PubMed Web of Science ®Google Scholar
• Lu X, Pan J, Tao J, et al. SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes. 2011;42(1):37–45.
   PubMed Web of Science ®Google Scholar
• Zhou R, To KK, Wong YC, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864–877.e5.
   PubMed Web of Science ®Google Scholar
• Liu W, Liu L, Kou G, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58(6):e00461. doi: 10.1128/jcm.00461-20.
   PubMed Web of Science ®Google Scholar
• Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848.
   PubMed Web of Science ®Google Scholar
• Paces J, Strizova Z, Smrz D, et al. COVID-19 and the immune system. Physiol Res. 2020;69(3):379–388.
   PubMed Web of Science ®Google Scholar
• Yu HQ, Sun BQ, Fang ZF, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020;56(2):2001526. doi: 10.1183/13993003.01526-2020.
   PubMed Web of Science ®Google Scholar
• Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta. 2020;507:164–166.
   PubMed Web of Science ®Google Scholar
• Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–775.
   PubMed Web of Science ®Google Scholar
• Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52(5):731–733.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607–613.
   PubMed Web of Science ®Google Scholar
• Lagunas-Rangel FA, Chavez-Valencia V. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients. J Med Virol. 2020;92:1789–1790.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu L, Tang L, et al. A promising anti-cytokine-storm targeted therapy for COVID-19: the artificial-liver blood-purification system. Engineering (Beijing). 2020. doi: 10.1016/j.eng.2020.03.006.
   Google Scholar
• Elkahloun AG, Saavedra JM. Candesartan could ameliorate the COVID-19 cytokine storm. Biomed Pharmacother. 2020;131:110653.
   PubMed Web of Science ®Google Scholar
• Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16(1):69–86.
   PubMed Web of Science ®Google Scholar
• Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly. 2020;150:w20249.
   PubMed Web of Science ®Google Scholar
• Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676.
   PubMed Web of Science ®Google Scholar
• Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17-18):2273–2279.
   PubMed Web of Science ®Google Scholar
• Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72–73.
   PubMed Web of Science ®Google Scholar
• Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615–632.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501. e15.
   PubMed Web of Science ®Google Scholar
• Brown M. Immune correlates of SARS-CoV-2 protection. Nat Rev Immunol. 2020;20(10):593
   PubMedGoogle Scholar
• Callow KA, Parry HF, Sergeant M, et al. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435–446.
   PubMed Web of Science ®Google Scholar
• Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
   PubMed Web of Science ®Google Scholar
• Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792–795.
   PubMed Web of Science ®Google Scholar
• Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–1564.
   PubMed Web of Science ®Google Scholar
• Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691–1693.
   PubMed Web of Science ®Google Scholar
• Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19. doi: .
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844.
   PubMed Web of Science ®Google Scholar
• Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020. doi: 10.1038/s41586-020-2700-3.
   Web of Science ®Google Scholar
• Van Vinh Chau N, Lam VT, Dung NT, et al. The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2020;ciaa711. doi: 10.1093/cid/ciaa711.
   Google Scholar
• Poletti P, Tirani M, Cereda D, et al. Probability of symptoms and critical disease after SARS-CoV-2 infection. arXiv preprint arXiv:200608471. 2020;
   Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv. 2020;
   Google Scholar
• Denison MR, Graham RL, Donaldson EF, Eckerle LD, et al. Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol. 2011;8(2):270–279.
   PubMed Web of Science ®Google Scholar
• Hofer U. Viral evolution: fooling the coronavirus proofreading machinery. Nat Rev Microbiol. 2013;11(10):662–663.
   PubMed Web of Science ®Google Scholar
• Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020;7(6):1012–1023. doi: 10.1093/nsr/nwaa036.
   PubMed Web of Science ®Google Scholar
• Forster P, Forster L, Renfrew C, et al. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020;117(17):9241–9243.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 Spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–1294 e9.
   PubMed Web of Science ®Google Scholar
• Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ. 2020;369:m2263
   PubMedGoogle Scholar
• Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results. medRxiv. 2020.
   Google Scholar
• Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J. 2020;96(1139):550–555.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949
   PubMed Web of Science ®Google Scholar
• Sahraei Z, Shabani M, Shokouhi S, et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55(4):105945
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New Engl J Med. 2020;383(21):2030–2040.
   Web of Science ®Google Scholar
• Srinivas P, Sacha GL, Koval C. Antivirals for COVID-19. Cleve Clin J Med. 2020. doi: 10.3949/ccjm.87a.ccc030.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi: 10.1016/S0140-6736(20)31022-9.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med. 2020;383(19):1827–1837.
   Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, GS-US-540-5774 Investigators, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. New Engl J Med. 2020;383(19):1813–1826.
   Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60(5):1648–1661.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, Jr., et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303.
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US). Remdesivir. 2006. 2020.
   Google Scholar
• Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother. 2002;3(3):315–327.
   PubMedGoogle Scholar
• Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4(5):1023–1033.
   PubMedGoogle Scholar
• Horby PW, Mafham M, Bell JL, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352. doi: 10.1016/S0140-6736(20)32013-4.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512
   PubMed Web of Science ®Google Scholar
• Du Y-X, Chen X-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020;108(2):242–247. doi: 10.1002/cpt.1844.
   PubMed Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859.
   PubMed Web of Science ®Google Scholar
• Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–e3.
   PubMed Web of Science ®Google Scholar
• Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6(1):1–5.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020;34(3):1241–1243.
   Google Scholar
• Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ. 2020;369:m2422
   PubMedGoogle Scholar
• Johnson RM, Vinetz JM. Dexamethasone in the management of covid -19. BMJ. 2020;370:m2648
   PubMedGoogle Scholar
• Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399. doi: 10.1128/AAC.00399-20.
   PubMed Web of Science ®Google Scholar
• Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. 01 May 2020. Available on: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment.
   Google Scholar
• U.S. Food and Drug Administration. FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. 28 Aug 2020. Available on: https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized.
   Google Scholar
• U.S. Food and Drug Administration. FDA Approves First Treatment for COVID-19. 22 Oct 2020. Available on: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.
   Google Scholar
• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with covid-19 — preliminary report. New Engl J Med. 2020. doi: 10.1056/NEJMoa2021436.
   Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571–587.
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020;382(25):2411–2418.
   PubMed Web of Science ®Google Scholar
• Page RL, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):e32–e69.
   PubMed Web of Science ®Google Scholar
• Kotecha P, Light A, Checcucci E, et al. Repurposing of drugs for Covid-19: a systematic review and meta-analysis. Panminerva Med. 2020. doi: 10.23736/S0031-0808.20.04024-0.
   Web of Science ®Google Scholar
• Zhu Y, Yu D, Yan H, et al. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol. 2020;94(14):e00635-20. doi: 10.1128/JVI.00635-20.
   Web of Science ®Google Scholar
• Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–331.
   PubMed Web of Science ®Google Scholar
• Mucha SR, Quraishy N. Convalescent plasma for COVID-19: Promising, not proven. Cleve Clin J Med. 2020;87(11):664–670. doi: .
   Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251
   PubMed Web of Science ®Google Scholar
• Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–295.
   PubMed Web of Science ®Google Scholar
• Tai W, Zhang X, He Y, et al. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020;179:104820
   PubMed Web of Science ®Google Scholar
• Dong J, Huang B, Jia Z, et al. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. Emerg Microbes Infect. 2020;9(1):1034–1036.
   PubMed Web of Science ®Google Scholar
• Hanke L, Vidakovics Perez L, Sheward DJ, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun. 2020;11(1):4420
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–449.
   PubMed Web of Science ®Google Scholar
• Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–1285.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19 . Front Immunol. 2020;11:1061
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20(10):585–586.
   PubMed Web of Science ®Google Scholar
• Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020;88:106903
   PubMed Web of Science ®Google Scholar
• Andreakos E, Tsiodras S. COVID-19: lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 2020;12(6):e12465
   PubMed Web of Science ®Google Scholar
• Shete A. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19. Int J Infect Dis. 2020;96:348–351.
   PubMed Web of Science ®Google Scholar
• Wu Y. Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. Virol Sin. 2020;35(3):256–258.
   PubMed Web of Science ®Google Scholar
• Golchin A, Farahany T Z. Biological products: cellular therapy and FDA approved products. Stem Cell Rev and Rep. 2019;15(2):166–175. doi: 10.1007/s12015-018-9866-1.
   PubMed Web of Science ®Google Scholar
• Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep. 2020;26:e00467 doi: 10.1016/j.btre.2020.e00467.
   Google Scholar
• Golchin A, Farahany TZ, Khojasteh A, et al. The Clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review. CSCR. 14(1):22–33. doi: 10.2174/1574888X13666180913123424.
   Google Scholar
• Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9(1):601–604.
   PubMed Web of Science ®Google Scholar
• Solerte SB, Di Sabatino A, Galli M, et al. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57(7):779–783.
   PubMed Web of Science ®Google Scholar
• Yang Y, Islam MS, Wang J, et al. Traditional chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci. 2020;16(10):1708–1717.
   PubMed Web of Science ®Google Scholar
• Khalili JS, Zhu H, Mak NSA, et al. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746.
   PubMed Web of Science ®Google Scholar
• Fu L, Ye F, Feng Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020;11(1):4417
   PubMed Web of Science ®Google Scholar
• Tambo E, Khater EIM, Chen J-H, et al. Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty. Infect Dis Poverty. 2015;4(1):58
   PubMedGoogle Scholar
• Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593–602.
   PubMed Web of Science ®Google Scholar
• Chaccour C, Hammann F, Ramon-Garcia S, et al. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;102(6):1156–1157.
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787
   PubMed Web of Science ®Google Scholar
• Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip. 2020;34(1):469–474.
   Web of Science ®Google Scholar
• Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther. 2020;108(4):762–765. doi: 10.1002/cpt.1889.
   PubMed Web of Science ®Google Scholar
• Levy M, Martin L, Bursztejn AC, the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, et al. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol. 2020;182(4):1003–1006. doi: 10.1111/bjd.18369.
   PubMed Web of Science ®Google Scholar
• Górski A, Międzybrodzki R, Żaczek M, et al. Phages in the fight against COVID-19? Future Microbiol. 2020;15:1095–1100.
   PubMed Web of Science ®Google Scholar
• Papadopoulos C, Patoulias D, Teperikidis E, et al. Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review. SN Compr Clin Med. 2020;2(9):1–11.
   Google Scholar
• Deftereos SG, Giannopoulos G, Vrachatis DA, GRECCO-19 investigators, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3(6):e2013136
   PubMed Web of Science ®Google Scholar
• Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020;79(10):1286–1289. doi: 10.1136/annrheumdis-2020-217712.
   PubMed Web of Science ®Google Scholar
• Lee CH, Koohy H. In silico identification of vaccine targets for 2019-nCoV. F1000Res. 2020;9:145.
   PubMedGoogle Scholar
• Zhang J, Zeng H, Gu J, et al. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel). 2020;8(2):153. doi: 10.3390/vaccines8020153.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Draft landscape of COVID-19 candidate vaccines. 19 October 2020. Available on: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi: 10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Wilkie M, Satti I, Minhinnick A, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2020;38(4):779–789.
   PubMed Web of Science ®Google Scholar
• Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020;8(11):e85–e86.
   Google Scholar
• Novavax, Inc. Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020. 20 Oct 2020. Available on: https://ir.novavax.com/news-releases/news-release-details/novavax-present-covid-19-vaccine-data-world-vaccine-congress.
   Google Scholar
• Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–12215.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351–2356.
   PubMed Web of Science ®Google Scholar
• Callaway E. Coronavirus vaccines: five key questions as trials begin. Nature. 2020;579(7800):481
   PubMed Web of Science ®Google Scholar
• Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963
   PubMed Web of Science ®Google Scholar
• Gerdts V, Zakhartchouk A. Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses. Vet Microbiol. 2017;206:45–51.
   PubMed Web of Science ®Google Scholar
• Aspinall R, Del Giudice G, Effros RB, et al. Challenges for vaccination in the elderly. Immun Ageing. 2007;4:9
   PubMedGoogle Scholar
• Koti M, Morales A, Graham CH, et al. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy. J Immunother Cancer. 2020;8(2):e001119. doi: 10.1136/jitc-2020-001119.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020;17(6):316–317.
   PubMed Web of Science ®Google Scholar
• Kumar J, Meena J. Demystifying BCG vaccine and COVID-19 relationship. Indian Pediatr. 2020;57(6):588–589. doi: 10.1007/s13312-020-1872-0.
   PubMed Web of Science ®Google Scholar
• Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine-induced protection from COVID-19 infection, wishful thinking or a game changer? medRxiv. 2020;
   Google Scholar
• Mohapatra PR, Mishra B, Behera B. BCG vaccination induced protection from COVID-19. Indian J Tuberculosis. 2020. doi: .
   PubMedGoogle Scholar
• Fidel PL, Jr., Noverr MC. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? mBio. 2020;11(3):e00907-20. doi: 10.1128/mBio.00907-20.
   Web of Science ®Google Scholar
• Sidiq KR, Sabir DK, Ali SM, et al. Does early childhood vaccination protect against COVID-19? Front Mol Biosci. 2020;7:120
   PubMed Web of Science ®Google Scholar